Posted on advfn3 Dec 2023 12:13
So as you can see from there website lots going on and more all for the share price of just over 1p now if that was not a good buy i dont know what is I rest my case in regards to Aptamer group DYOR and its clear this company is turning a corner
bigruss1
Read Full Thread
Reply
03/12/2023
01:02 Aptamer Group is working with Cancer Research UK and Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester. The project will explore the potential of bifunctional Optimer® therapeutics for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies.
This multi-target agreement with PinotBio will develop Optimer®-drug conjugates for the treatment of different cancer diseases.
Following success of the initial proof-of-concept study, Aptamer Group will develop Optimer® delivery vehicles to non-blood based cancer biomarkers. These will be provided to PinotBio for use with their payload and linker technologies. PinotBio will generate the full Optimer®-drug conjugates and perform initial animal studies to evaluate the conjugate molecules and their potential to progress as clinical candidates.
Both parties will jointly own the developed assets, with each party retaining ownership over the conjugate’s individual components. If successful these therapeutic modalities will open opportunities for downstream value creation in the form of licensing fees, milestones, and or royalties.
Aptamer Group will develop validated Optimer® binders against critical targets for ProAxsis’s diagnostic assays. ProAxsis will then assess Optimer® performance within their current diagnostics assays, with the view to potentially replacing the antibodies in their commercial diagnostic assays.
Aptamer Group will be working in collaboration with ValitaCell to engineer a next-generation platform, in which Optimer® binders enable ValitaCell’s high throughput screening processes to new biologic targets. These screening processes can rapidly identify promising molecules and cell lines that could go on to be developed into new therapeutic drugs.
This partnership will focus on developing new affinity resins to improve the purification and scale-up of gene therapy vectors. Aptamer Group will develop an Optimer® capable of binding and eluting a viral vector. Bio-Works Technologies will then develop a derivatized resin by coupling the Optimer® to its patented WorkBeads™ agarose beads.
As part of this Optimer® binders will be developed, with the potential for incorporation into Takeda’s drug development process.
Following the development of specific Optimer® binders to the agreed range of targets, the Optimer® binders will be available to Takeda to evaluate for the feasibility of working within their internal drug development processes.
Aptamer is working with BaseCure Therapeutics to identify cell targeting Optimer® binders to be developed as potential delivery vehicles to increase